Staging is the process of learning how much cancer is in your body and where it is. For endometrial cancer, tests like ultrasound, biopsy, dilation and curettage (D&C), X-Ray, CT scan, MRI, PET scan, and cystoscopy and proctoscopy may be used to help stage your cancer. Blood tests, like a complete blood count (CBC) and tumor marker tests (such as CA-125) may also be done to help stage your cancer. Your providers need to know about your cancer and your health so that they can plan the best treatment for you.
Staging looks at the size of the tumor and where it is, and if it has spread to other organs. There are two staging systems used for endometrial cancer. The first system is called the FIGO (International Federation of Gynecology and Obstetrics) system. The second system is called the “TNM system,” as described by the American Joint Committee on Cancer. Both systems stage endometrial cancer based 3 factors:
Your healthcare provider will use the results of the tests you had to determine your FIGO and TNM result and combine these to get a stage from 0 to IV.
Staging of endometrial cancer is based on:
Staging may be done at different times during your treatment.
The staging system is very complex. Below is a summary. Talk to your provider about the stage of your cancer.
FIGO and AJCC Stage I (T1, N0, M0): The cancer is growing inside the uterus. It may also be growing into the glands of the cervix, but not into the nearby connective tissue of the cervix (T1). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
FIGO and AJCC Stage IA (T1a, N0, M0): The cancer is in the endometrium (inner lining of the uterus) and may have grown less than halfway through the muscle layer of the uterus (the myometrium) (T1a). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
FIGO and AJCC Stage IB (T1b, N0, M0): The cancer has grown from the endometrium into the myometrium. It has grown more than halfway through the myometrium but has not spread past the body of the uterus (T1b). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
FIGO and AJCC Stage II (T2, N0, M0): The cancer has spread from the body of the uterus and is growing into the supporting connective tissue of the cervix (called the cervical stroma). But it has not spread outside the uterus (T2). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
FIGO and AJCC Stage III (T3, N0, M0): The cancer has spread outside the uterus but has not spread to the inner lining of the rectum or urinary bladder (T3). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
FIGO and AJCC Stage IIIA (T3a, N0, M0): The cancer has spread to the outer surface of the uterus (the serosa) and/or to the fallopian tubes or ovaries (T3a). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
FIGO and AJCC Stage IIIB (T3b, N0, M0): The cancer has spread to the vagina or to the tissues around the uterus (T3b). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
FIGO and AJCC Stage IIIC1 (T1-T3, N1/N1mi/N1a, M0): The cancer is growing in the uterus. It may have spread to some nearby tissue but is not growing into the inside of the bladder or rectum (T1 to T3). It has also spread to pelvic lymph nodes (N1, N1mi, or N1a), but not to lymph nodes around the aorta or distant sites (M0).
FIGO and AJCC Stage IIIC2 (T1-T3, N2/N2mi/N2a, M0): The cancer is growing into the uterus. It may have spread to some nearby tissues but is not growing into the inside of the bladder or rectum (T1 to T3). It has also spread to lymph nodes around the aorta (N2, N2mi, or N2a), but not to distant sites (M0).
AJCC Stage IVA (T4, Any N, M0): The cancer has spread to the inner lining of the rectum or urinary bladder (T4). It may or may not have spread to nearby lymph nodes (Any N) but has not spread to distant sites (M0).
FIGO and AJCC Stage IVB (Any T, Any N, M1): The cancer has spread to inguinal (groin) lymph nodes, the upper abdomen (belly), the omentum (fatty tissue near your stomach and bowels), or to organs away from the uterus, such as the lungs, liver, or bones (M1). The cancer can be any size (Any T) and it may or may not have spread to other lymph nodes (Any N).
Treatment for endometrial cancer depends on many factors, like your cancer stage, age, overall health, and testing results. Your treatment may include:
The most common surgery used to treat endometrial cancer is a hysterectomy. During a hysterectomy, your uterus is removed. Your cervix, ovaries, fallopian tubes, and/or other nearby organs may also be removed. There are a few types of hysterectomy:
There are 3 ways to do a hysterectomy:
Radiation is the use of high-energy x-rays to kill cancer cells. Endometrial cancer is often treated with radiation therapy after surgery. Radiation is used to lower the chances that the cancer will come back (reoccurrence).
The most common types of radiation therapy used for endometrial cancer are:
Radiation can also be given with chemotherapy, called chemoradiation.
Chemotherapy is often used in stage III or stage IV endometrial cancer. In most cases, more than one chemotherapy will be used for your treatment. Chemotherapy medications used to treat endometrial cancer are paclitaxel, carboplatin, doxorubicin, liposomal doxorubicin, cisplatin, docetaxel, and ifosfamide.
Some cancers need hormones to grow. Blocking the action of these hormones might stop the cancer from growing. Hormone therapy is often given along with chemotherapy. Some hormone therapy medications used to treat endometrial cancer are medroxyprogesterone acetate, megestrol acetate, tamoxifen, goserelin acetate, leuprolide, letrozole, anastrozole, and exemestane.
Targeted therapy are medications that target something specific to the cancer cells, stopping them from growing and dividing. Some types of targeted therapy used for endometrial cancer are lenvatinib, bevacizumab, everolimus, and temsirolimus.
Immunotherapy is the use of medication to help your immune system fight cancer. Examples of immunotherapy medications used to treat endometrial cancer are pembrolizumab and dostarlimab. Both of these medications are immune checkpoint inhibitor medications that block a protein called PD-1. By blocking PD-1, these medications help your immune system decrease tumor size or slow down cancer cell division.
You may be offered a clinical trial as part of your treatment plan. To find out more about current clinical trials, visit the OncoLink Clinical Trials Matching Service.
Your care team will make sure you are included in choosing your treatment plan. This can be overwhelming as you may be given a few options to choose from. It feels like an emergency, but you can take a few weeks to meet with different providers and think about your options and what is best for you. This is a personal decision. Friends and family can help you talk through the options and the pros and cons of each, but they cannot make the decision for you. You need to be comfortable with your decision – this will help you move on to the next steps. If you ever have any questions or concerns, be sure to call your team.
You can learn more about endometrial cancer at OncoLink.org.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania